Update to Heron Therapeutics, Inc. (Nasdaq: HRTX)

Heron Therapeutics Receives Complete Response Letter For HTX-011 For The Management Of Postoperative Pain Heron received a complete response letter (CRL) from the U.S. Food and Drug Administration (FDA) on April 30, 2019.¹ A CRL is sent to drug manufacturers to indicate that the review cycle for an application is complete and that the application … Continue reading Update to Heron Therapeutics, Inc. (Nasdaq: HRTX)

Advertisement

Heron Therapeutics, Inc. (NASDAQ:HRTX)

Heron Therapeutics, Inc. is a company I see potential value in. I have not taken a position; however, this company is currently on my watch list. This company currently has two approved products, SUSTOL® (granisetron) and CINVANTI® (aprepitant). HTX-011 (bupivacaine and meloxicam) is their investigational product that has a Prescription Drug User Fee Act (PDUFA) date of 30 April 2019.